GS 9688

Drug Profile

GS 9688

Alternative Names: GS-9688

Latest Information Update: 25 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals
  • Mechanism of Action Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 17 May 2017 Phase-I clinical trials in Hepatitis B in Australia and South Korea (PO) before May 2017 (ACTRN12617000235303p)
  • 17 May 2017 Gilead Sciences initiates a phase I trial for Hepatitis B in Australia, South Korea and New Zealand before May 2017(ACTRN12617000235303p)
  • 17 May 2017 Gilead Sciences plans a phase I trial for Hepatitis B (In volunteers) in New Zealand (ACTRN12617000700336p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top